W Cai1, Q Li, Z Yang, X Miao, Y Wen, S Huang, J Ouyang. 1. Research Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Number 139, Renmin Road, Changsha, 410011, Hunan, People's Republic of China, caiwenwu1986@sina.com.
Abstract
PURPOSE: An increasing number of studies have shown that PUMA and C-myb signaling pathways are involved in various human cancers including colon carcinomas. However, few studies have examined gallbladder cancer specimens, and little is known about the clinical and pathological significance signaling changes may have in gallbladder adenocarcinoma. This study has investigated the expression of PUMA and C-myb in benign and malignant lesions of gallbladder and its pathological significance. METHODS: Tissue specimens from 108 gallbladder adenocarcinoma patients, 46 adjacent tissues, 15 cases of adenomatous polyps, and 35 surgical specimens from chronic cholecystitis patients were routinely paraffin embedded and sectioned. PUMA and C-myb expressions were detected with EnVision immunohistochemistry. RESULTS: Positive rates of PUMA and C-myb are significantly higher in gallbladder adenocarcinoma tissues than that in the other three (P < 0.01). Gallbladder epithelial cells in PUMA and/or C-myb positive benign cases manifest moderate to severe atypical dysplasia. Positive rates of PUMA and C-myb in well-differentiated tumors with maximum diameter of <2 cm and with no lymph node metastasis and invasion of the surrounding tissues are significantly lower than that in those poorly differentiated cases with maximum diameter of ≥ 2 cm, lymph node metastasis, and invasion of the surrounding tissues (P < 0.05 or P < 0.01). The postoperative survival of patients whose tumor specimens are positive for PUMA and C-myb is significantly shorter than that of those who are negative for both markers (P < 0.05 or P < 0.01). CONCLUSIONS: Our results have demonstrated that PUMA and C-myb positive gallbladder tumors progress rapidly, are prone to metastasis, possess strong invasive ability, and have poor prognosis.
PURPOSE: An increasing number of studies have shown that PUMA and C-myb signaling pathways are involved in various humancancers including colon carcinomas. However, few studies have examined gallbladder cancer specimens, and little is known about the clinical and pathological significance signaling changes may have in gallbladder adenocarcinoma. This study has investigated the expression of PUMA and C-myb in benign and malignant lesions of gallbladder and its pathological significance. METHODS: Tissue specimens from 108 gallbladder adenocarcinomapatients, 46 adjacent tissues, 15 cases of adenomatous polyps, and 35 surgical specimens from chronic cholecystitispatients were routinely paraffin embedded and sectioned. PUMA and C-myb expressions were detected with EnVision immunohistochemistry. RESULTS: Positive rates of PUMA and C-myb are significantly higher in gallbladder adenocarcinoma tissues than that in the other three (P < 0.01). Gallbladder epithelial cells in PUMA and/or C-myb positive benign cases manifest moderate to severe atypical dysplasia. Positive rates of PUMA and C-myb in well-differentiated tumors with maximum diameter of <2 cm and with no lymph node metastasis and invasion of the surrounding tissues are significantly lower than that in those poorly differentiated cases with maximum diameter of ≥ 2 cm, lymph node metastasis, and invasion of the surrounding tissues (P < 0.05 or P < 0.01). The postoperative survival of patients whose tumor specimens are positive for PUMA and C-myb is significantly shorter than that of those who are negative for both markers (P < 0.05 or P < 0.01). CONCLUSIONS: Our results have demonstrated that PUMA and C-myb positive gallbladder tumors progress rapidly, are prone to metastasis, possess strong invasive ability, and have poor prognosis.
Authors: Jean-Simon Diallo; Abdulhadi Aldejmah; Abdelali Filali Mouhim; Benjamin Péant; Mona Alam Fahmy; Ismaël Hervé Koumakpayi; Kanishka Sircar; Louis R Bégin; Anne-Marie Mes-Masson; Fred Saad Journal: Clin Cancer Res Date: 2007-12-01 Impact factor: 12.531
Authors: Frank A Sinicrope; Rafaela L Rego; Kenji Okumura; Nathan R Foster; Michael J O'Connell; Daniel J Sargent; Harold E Windschitl Journal: Clin Cancer Res Date: 2008-09-15 Impact factor: 12.531
Authors: J Brabender; R V Lord; K D Danenberg; R Metzger; P M Schneider; J M Park; D Salonga; S Groshen; D D Tsao-Wei; T R DeMeester; A H Hölscher; P V Danenberg Journal: J Surg Res Date: 2001-08 Impact factor: 2.192
Authors: Mohammad Obaidul Hoque; Shahnaz Begum; Matthias Sommer; Taekyeol Lee; Barry Trink; Edward Ratovitski; David Sidransky Journal: Cancer Lett Date: 2003-09-10 Impact factor: 8.679
Authors: Michal Tichý; Lucia Knopfová; Jiří Jarkovský; Lucie Pekarčíková; Lenka Veverková; Petr Vlček; Jana Katolická; Ivan Čapov; Markéta Hermanová; Jan Šmarda; Petr Beneš Journal: Tumour Biol Date: 2016-02-12